Veracyte in the news
October 3, 2024
Veracyte’s RNA Genetic Test Predicts Black Men’s Aggressive Prostate Cancer
Inside Precision Medicine
September 30, 2024
The Future is Bright for Veracyte and Molecular Diagnostics
OPTO
September 26, 2024
The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy
OPTO
September 15, 2024
Gerhard Attard, MD, on the interaction between Decipher score and docetaxel benefit
Urology Times
September 15, 2024
Veracyte’s CEO talks about ESMO data from it’s prostate cancer diagnostic that could change how metatstatic prostate cancer is treated
BiotechTV
August 7, 2024
Veracyte Q2 Revenues up 27 Percent on Prostate, Thyroid Tests; Firm Raises Full-Year Guidance
GenomeWeb
July 12, 2024
Genomic Testing Helps Personalize Care for Prostate Cancer Patients
Oncology Times